Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial of Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product in Healthy Subjects

Next Previous
Trial Profile

A Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial of Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
  • Focus Pharmacokinetics

Most Recent Events

  • 09 May 2023 Results presented at the Digestive Disease Week 2023
  • 28 Dec 2022 New trial record
  • 14 Nov 2022 Results on the PK equivalence of MSB11022-acetate and US-RP presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top